Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from
genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte
maturation triggering in assisted reproductive technology (ART).Recombinant hCG has been
investigated about its safety and efficacy comparing with urinary hCG, but still the optimal
dose of rhCG is questionable. From former studies, there only have been proven that high dose
of hCG can make ovarian hyperstimulation syndrome (OHSS) in usual condition. On the other
hand, we hypothesize that high dose of hCG may improve oocyte maturity in poor responders who
cannot easily provoke OHSS. Hence, this study will assess the comparative efficacy and safety
of 250mcg and 500mcg of rhCG in ART treatment cycle.